Bacteriological and clinical studies on meropenem

Yoshiro Sawae, Nobuyuki Shimono, Hiroyasu Misumi, Katsuhiko Eguchi, Atsushi Takita, Kazuyuki Higuchi, Kaoru Okada, Masahide Takii, Michio Fukuma, Kiyoshi Ninomiya, Tsukasa Oshima, Ikuo Sumita, Takatoshi Inoue, Yukio Kumagai, Toshiyuki Ishimaru

Research output: Contribution to journalArticlepeer-review


We performed bacteriological and clinical studies on meropenem (MEPM), a new parenteral carbapenem antibiotic, with the following results. 1. Antibacterial activity The MICs of MEPM against various clinical isolates were detemined with an inoculum size of 106 cell/ml. The MIC90 was 6.25 µg/ml for Staphylococcus aureus, 25 for Enterococcus faecalis, ≦0.05 for Escherichia coli, 0.1 for Klebsiella pneumoniae, Proteus mirabilis and Proteus vulgaris, 1.56 for Enterobacter cloacae, 3.13 for Enterobacter aerogenes, 0.39 for Serratia marcescens, 0.78 for Citrobacter freundii and, 50 for Pseudomonas aeruginosa. Its activity against gram-positive cocci was less than that of imipenem (IPM), but against gram-negative rods other than P. aeruginosa its activity was more potent than IPM, ceftazidime (CAZ) cefoperazone (CPZ), and piperacillin (PIPC). Its activity against P. aeruginosa was the same as that of IPM and CAZ, but more active than CPZ and PIPC.

Original languageEnglish
Pages (from-to)401-411
Number of pages11
Publication statusPublished - Apr 1992

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Bacteriological and clinical studies on meropenem'. Together they form a unique fingerprint.

Cite this